The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
ALS patients experience neuroinflammation and rapid neurodegeneration
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
ORACEA is a trademark of Galderma Holdings, S.A.
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Subscribe To Our Newsletter & Stay Updated
